| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the de...
 
																	 
																	HC Wainwright & Co. analyst Ed Arce reiterates Paratek Pharmaceuticals (NASDAQ:PRTK) with a Neutral and maintains $2.15 ...
 
																	 
																	 
																	Transaction Provides Paratek Stockholders with Immediate Value and Liquidity Stockholders to Receive Upfront Cash Payment of...
 
																	HC Wainwright & Co. analyst Ed Arce reiterates Paratek Pharmaceuticals (NASDAQ:PRTK) with a Neutral and maintains $2.15 ...
 
																	-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones -- ...
 
																	Paratek Pharmaceuticals, Inc. ("Paratek") (NASDAQ:PRTK), a commercial-stage biopharmaceutical company focused on the d...